The China Mail - Inspire Veterinary Partners Issues Corporate Update Letter to Shareholders

USD -
AED 3.672503
AFN 68.45856
ALL 84.12756
AMD 381.570655
ANG 1.789783
AOA 916.999843
ARS 1355.982501
AUD 1.545523
AWG 1.8
AZN 1.699474
BAM 1.688422
BBD 2.013873
BDT 121.680652
BGN 1.688185
BHD 0.377007
BIF 2981.344475
BMD 1
BND 1.289231
BOB 6.907209
BRL 5.442199
BSD 0.999599
BTN 87.778411
BWP 13.486366
BYN 3.396857
BYR 19600
BZD 2.010437
CAD 1.38505
CDF 2867.501836
CHF 0.80648
CLF 0.024674
CLP 967.949906
CNY 7.152902
CNH 7.16367
COP 4053.99
CRC 503.295593
CUC 1
CUP 26.5
CVE 95.190614
CZK 21.170102
DJF 178.008754
DKK 6.43899
DOP 62.778411
DZD 130.331833
EGP 48.650501
ERN 15
ETB 141.839764
EUR 0.86257
FJD 2.269202
FKP 0.741734
GBP 0.744095
GEL 2.694978
GGP 0.741734
GHS 11.145979
GIP 0.741734
GMD 71.528078
GNF 8666.563072
GTQ 7.662557
GYD 209.052375
HKD 7.783005
HNL 26.189613
HRK 6.502601
HTG 130.840153
HUF 342.303502
IDR 16422.8
ILS 3.34274
IMP 0.741734
INR 87.757204
IQD 1309.610138
IRR 42049.999945
ISK 123.359904
JEP 0.741734
JMD 159.751718
JOD 0.709046
JPY 148.051016
KES 129.160062
KGS 87.425302
KHR 4006.543762
KMF 423.250062
KPW 900.015419
KRW 1397.839891
KWD 0.30582
KYD 0.833078
KZT 539.029317
LAK 21692.831645
LBP 89517.721251
LKR 302.142684
LRD 200.428188
LSL 17.761577
LTL 2.95274
LVL 0.60489
LYD 5.424048
MAD 9.059964
MDL 16.524295
MGA 4418.334621
MKD 53.126834
MMK 2099.054675
MNT 3597.17449
MOP 8.014451
MRU 39.985842
MUR 46.390049
MVR 15.409647
MWK 1733.211323
MXN 18.731015
MYR 4.235019
MZN 63.949704
NAD 17.761577
NGN 1534.71969
NIO 36.784765
NOK 10.16829
NPR 140.445112
NZD 1.71637
OMR 0.384514
PAB 0.999607
PEN 3.547602
PGK 4.228392
PHP 57.255505
PKR 283.59655
PLN 3.682785
PYG 7225.732933
QAR 3.646448
RON 4.3703
RSD 101.07303
RUB 80.300032
RWF 1447.483716
SAR 3.752228
SBD 8.217066
SCR 14.787745
SDG 600.497618
SEK 9.58797
SGD 1.288969
SHP 0.785843
SLE 23.249996
SLL 20969.49797
SOS 571.324977
SRD 38.324498
STD 20697.981008
STN 21.150501
SVC 8.746849
SYP 13002.232772
SZL 17.748368
THB 32.487497
TJS 9.521606
TMT 3.5
TND 2.932422
TOP 2.342097
TRY 41.023019
TTD 6.796707
TWD 30.645022
TZS 2502.03204
UAH 41.295021
UGX 3561.932387
UYU 39.978936
UZS 12350.219276
VES 141.606965
VND 26370
VUV 119.58468
WST 2.776302
XAF 566.283221
XAG 0.026081
XAU 0.000296
XCD 2.70255
XCG 1.801599
XDR 0.701052
XOF 566.280776
XPF 102.955903
YER 240.174983
ZAR 17.76462
ZMK 9001.177673
ZMW 23.366757
ZWL 321.999592
  • RBGPF

    1.4500

    77

    +1.88%

  • RYCEF

    0.0800

    14.42

    +0.55%

  • CMSC

    -0.0918

    23.77

    -0.39%

  • VOD

    0.1200

    11.98

    +1%

  • BP

    0.0750

    34.745

    +0.22%

  • GSK

    0.0530

    39.883

    +0.13%

  • RIO

    -0.1300

    61.82

    -0.21%

  • RELX

    0.1050

    47.965

    +0.22%

  • NGG

    0.5200

    71.56

    +0.73%

  • SCS

    -0.0400

    16.58

    -0.24%

  • BTI

    -0.4850

    56.845

    -0.85%

  • CMSD

    -0.0200

    23.85

    -0.08%

  • BCC

    -0.6700

    88.18

    -0.76%

  • AZN

    -0.3350

    79.715

    -0.42%

  • BCE

    0.0850

    24.985

    +0.34%

  • JRI

    0.0390

    13.399

    +0.29%

Inspire Veterinary Partners Issues Corporate Update Letter to Shareholders
Inspire Veterinary Partners Issues Corporate Update Letter to Shareholders

Inspire Veterinary Partners Issues Corporate Update Letter to Shareholders

VIRGINIA BEACH, VA / ACCESS Newswire / February 12, 2025 / Inspire Veterinary Partners, Inc. (Nasdaq:IVP) ("Inspire" or the "Company"), an owner and provider of pet health care services throughout the U.S.,today issued a letter to stockholders from Kimball Carr, the Chief Executive Officer of Inspire.

Text size:

Dear Shareholders,

As 2024 has drawn to a close and Inspire Veterinary Partners pursues its growth plans for 2025 and beyond, I'd like to share some detail on how the team at Inspire has been engaged toward achieving our goals.

The opportunity to become a publicly traded veterinary company provided us with additional capabilities to fuel growth and to attract and retain talented employees. It also brings a new set of obligations and responsibilities that must be navigated, often requiring adjustment and reassessment of strategy and processes. In 2024, market forces, the challenges of lending and capital markets and the trends within our veterinary medicine industry were all factors that impacted our performance and tested our management team. This set of circumstances required us to look internally and devise and implement initiatives that would enable us to prosper in this environment and position us better for future growth.

The result of our collective work has made us stronger - with systems, tools and teams built for growth. We invested over this past year while we also paying down debt and addressing excess costs. We brought new levels of efficiency to our operations at every level, and we upgraded leadership on a wide variety of fronts. In doing all the above, we've remained acutely aware that our performance as a public company in 2024 was disappointing. Market conditions were not ideal for small and microcap listed companies, but despite the outside factors which IVP faced, we take full accountability for growing our company in ways which provide benefit for our clients and team as well as value for our shareholders. That said, as of February 2025, we are informed by Nasdaq that we have also regained our bid price compliance, adding that to the shareholder equity compliance which we regained in late 2024. The resolution of these issues makes us fully compliant with Nasdaq.

While this past year has had its share of frustrations, our team and I have been engaged every single day on improvements, advancements and the right investments which we believe will bring the growth we all desire.

Operations Excellence

  • IVP has built our framework with an immense focus on the balance between the belief that we 'can't save our way to success' - meaning, we must grow to succeed - and, avoiding fallacy that all problems go away by 'throwing money at them'. To achieve this balance, we have scrutinized our labor spend at all levels, been cautious in headcount adds and managing costs closely by eliminating dependance on unnecessary facilities or offices.

  • Within the veterinary channel, the decades-long growth of our industry exploded further during the pandemic era. In the period afterward, we have seen a variety of dynamics. These conditions impacted worker engagement, the costs of supplies and services and the climate within which we seek to purchase existing businesses to add to our portfolio. Related to our core/comp business and our business development arm, we have:

    • Implemented new strategies and tools that are bringing in new clients, filling our schedules more effectively and bringing our clinics to better productivity.

    • Completed companywide integrations across accounting platforms, practice management software and key performance indicator (KPI) reporting systems. This work over the last year has made IVP a fully integrated company with remote view and cloud-based management of every system we use. These rollouts allow decentralized management and provide a framework for all our clinics to work under the same systems and reporting tools so that we have consistency in the growth measures we implement across our portfolio. We believe the result of all of this will be faster improvement and easier integration of each new business unit we acquire.

    • We invested in improved unit managers and built new job leveling programs which allow our leaders to progress in their careers with IVP.

    • We've added experienced clinical recruiting leadership and, as a result, rebuilt our entire talent selection process, resulting in measurable gains in our onboarding of much-needed clinical talent when compared to one year ago.

    • We've onboarded experienced business development leadership and re-engineered our M&A workflow to evaluate new acquisition targets more efficiently and with far more market data than previously available.

    • Finally, we enhanced our relationships with major suppliers and service providers in the veterinary space, providing IVP the ability to begin to use its size toward economies that come with our growing scale.

  • All these innovations and workstreams have been a benefit to our costs, revenue and overall operations. They also represent only a portion of the agility IVP has demonstrated in the past year - a year in which we believe our company faired far better than some other providers in the veterinary space which had their own challenges.

Treasury Management

  • IVP continues to operate via a 'lean management while building for growth' mindset and, as such, we have paid down balances on both long- and short-term debt while being judicious about how and when we take capital into the company.

  • Our work toward more efficient capital strategies, well-prepared audit processes and improved operations has contributed positively toward efficiency and allowed us to find savings across a variety of expense categories.

Differentiated Approach

  • Over the past two years, the team at IVP has designed, approved and prepared an ESOP equity plan which will be the framework for our goal of shared ownership with all team members. We expect to launch this program in 2025, becoming the first of its kind in veterinary medicine and positioning IVP as an employer of choice in our sector.

  • Having committed to taking great care of our professionals early on our journey, in the last year we further enhanced our total compensation and benefits plans, seeking to include health, vision, dental, well-being, retirement and other compensation offerings that we believe are superior to many other companies in the veterinary channel. By building one of the most robust models in veterinary medicine, we look forward to adding shared equity as the final piece of a suite of rewards aimed at recognizing and rewarding our team members.

  • And, we've remained true to respecting clinical professionals in our sector via customized employment structures. We have achieved this through our commitment to no negative earnings accruals for veterinarians, no non-compete restrictions for associate doctors and the ability for us to build models which work for doctors and the ways in which they want to practice veterinary medicine.

Looking Ahead

In 2025 and the years beyond, our team is focused on the growth of Inspire's core business, within our M&A strategy and for new verticals and business models which we are actively evaluating. We are a young company, but we've built leaders and systems for the future - with a rock-solid devotion to scaling thoughtfully. As such, we will remain conservative in our forecasts, valuations and outlook on innovations and new facility opportunities. We will avoid trends or whims in our marketplace, choosing to base our decisions on measurable returns and realistic value models.

We have built a world-class team who have proven track records, and they have joined IVP to build a company they can be proud of. This is a team of achievers, innovators and leaders and I am incredibly proud of the work they are doing.

For those who have supported us, watched our journey and been instrumental in what we have achieved thus far, I thank you and I look forward to sharing opportunities for us to celebrate new achievements this year and beyond.

Thank you and all the best.

Kimball Carr

President / CEO

Inspire Veterinary Partners

About Inspire Veterinary Partners, Inc.

Inspire Veterinary Partners is an owner/operator of veterinary hospitals in the US. As the Company expands, it expects to acquire additional veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care.

For more information, please visit: www.inspirevet.com.

Connect with Inspire Veterinary Partners, Inc.

Facebook

https://www.facebook.com/InspireVeterinaryPartners/

LinkedIn

https://www.linkedin.com/company/inspire-veterinary-partners/

Forward-Looking Statements

This press release contains forward-looking statements regarding the Company's current expectations. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the satisfaction of customary closing conditions related to anticipated acquisitions, or factors that result in changes to the Company's anticipated results of operations related to acquisitions. These and other risks and uncertainties are described more fully in the section captioned "Risk Factors" in the Company's public filings made with the Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

Investor Contact

TraDigital IR
Kevin McGrath
+1-646-418-7002
[email protected]

General Inquires

Morgan Wood
[email protected]

SOURCE: Inspire Veterinary Partners, Inc.



View the original press release on ACCESS Newswire

V.Liu--ThChM